Phase 2 Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your blood tests show a specific antibody called an "acetylcholine receptor antibody" (AChR-Ab), which is linked to myasthenia gravis
- You have been diagnosed with a form of myasthenia gravis called "generalized myasthenia gravis" (gMG) and your condition falls within a certain range of severity (classified as Class II, III, IVa, or IVb — confirm with trial site for what this means for you)
- You have received certain vaccinations (against meningococcal and pneumococcal bacteria) within the last 5 years, or you are willing to receive these vaccinations at least 14 days before starting the trial treatment
Who may not be able to join:
- You have been diagnosed with systemic lupus erythematosus (SLE), sometimes called "lupus"
- You have a known deficiency in a part of your immune system called the "complement system" (confirm with trial site)
- You are currently taking, or have recently taken, certain medications that affect the complement system, including zilucoplan, eculizumab, or ravulizumab (the required time since stopping these varies — confirm with trial site)
- You have previously tried a treatment called efgartigimod and it did not improve your myasthenia gravis symptoms enough to be considered meaningful
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 857-350-4834
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events and serious adverse events in parts A and B
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.